Achondroplasia Treatment in United Arab Emirates

What is Achondroplasia?

Achondroplasia is a hereditary bone disorder that results in disproportionate short stature. The disorder results from a mutation in the FGFR3 gene, leading to abnormal cartilage and bone development. It is characterised by short hands and legs, a large head, prominent forehead, flat face, short fingers, and spinal or lower limb deformities. Most individuals with the condition have normal intelligence. Achondroplasia is a lifelong genetic condition, but proper medical supervision can help manage it and reduce complications.

What is the Importance of Timely Treatment?

Currently, there is no cure for achondroplasia, but it is possible to avoid, determine, or treat complications by conducting surgeries when necessary. Constant monitoring is essential in patients’ early years because they may develop complications involving the foramen magnum, spine, breathing, hearing, and movement that require intervention.

Timely treatment helps detect complications early, monitor growth, manage skeletal and neurological concerns, support mobility, provide rehabilitation, and promote greater independence and quality of life.

What are the Common Symptoms of Achondroplasia?

The features can vary between individuals. Common characteristics include:

• Disproportionately short stature
• Shortening of the upper arms and thighs
• Relatively large head size
• Prominent forehead
• Midface retrusion
• Short fingers with a characteristic hand configuration
• Limited elbow extension
• Bowing of the legs
• Increased lumbar curvature
• Thoracolumbar kyphosis, particularly during infancy
• Delayed motor milestones in some children
• Recurrent middle-ear problems
• Sleep-disordered breathing or obstructive sleep apnea
• Spinal stenosis, particularly in older children and adults
• Neurological symptoms caused by spinal or craniocervical compression

Causes and Risk Factors of Achondroplasia

Causes

• Achondroplasia is caused by a pathogenic mutation in the FGFR3 gene, which disrupts normal cartilage-to-bone development and limits long-bone growth.
• The mutation increases FGFR3 activity, interfering with normal skeletal growth and bone development.
• Around 80% of cases result from new genetic mutations that occur for the first time in the affected individual rather than being inherited.

Risk Factors

• Autosomal Dominant Inheritance
• No Lifestyle-Related Risk Factors
• Usually No Family History

Latest Research and Technologies in the Treatment of Achondroplasia in the United Arab Emirates

• The United Arab Emirates is increasingly adopting multidisciplinary, newer approaches to achondroplasia management, tailoring treatment plans to the patient’s age, symptoms, growth pattern, and complications. Newer targeted therapies that address FGFR3-related growth signalling are changing the treatment landscape for eligible children where approved and clinically appropriate. Management can involve orthopaedic care, physiotherapy, airway and sleep interventions, and treatment of spinal complications.